Home / Journals / CJU / Vol.28, No.3, 2021
Special Issues
  • Open AccessOpen Access

    EDITORIAL

    Keeping Our Morcellators Straight in Minimally Invasive Surgery

    Leonard G. Gomella
    Canadian Journal of Urology, Vol.28, No.3, pp. 10652-10652, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LEGENDS IN UROLOGY

    LEGENDS IN UROLOGY

    Derek Raghavan
    Canadian Journal of Urology, Vol.28, No.3, pp. 10653-10656, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LETTER

    Re: Abramowitz et al. “Virtue male sling outcomes and application to a contemporary nomogram”

    Nabeel A. Shakir
    Canadian Journal of Urology, Vol.28, No.3, pp. 10657-10657, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LETTER

    Re: Abramowitz et al. “Virtue male sling outcomes and application to a contemporary nomogram”

    Jonathan N. Warner, David Abramowitz
    Canadian Journal of Urology, Vol.28, No.3, pp. 10658-10658, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    REVIEW

    Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine

    Cord J. Peters1, Clesson E. Turner2, Gregory T. Chesnut3,4, Veda N. Giri5,6, Leonard G. Gomella5, Craig D. Shriver3,7, Albert Dobi3
    Canadian Journal of Urology, Vol.28, No.3, pp. 10659-10667, 2021
    Abstract Introduction: The objective of our review is to summarize the 2019 Philadelphia Prostate Cancer Genetic Consensus recommendations and discuss their implications to the US Military Health System.
    Materials and methods: Literature review.
    Results: Our fighting force and retired service members will significantly benefit from the Philadelphia Prostate Cancer Genetic Consensus recommendations. Moreover, the experience of the equal access US Military Health System may help advancing genetic testing for cancer at national levels.
    Conclusions: Priorities recommended by the 2019 Consensus for more research on genetic predisposition to prostate cancer in racially diverse populations is a promising step. The US Military More >

  • Open AccessOpen Access

    COMMENTARY

    Re: Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine

    Judd W. Moul
    Canadian Journal of Urology, Vol.28, No.3, pp. 10668-10668, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    HOW I DO IT

    How I Do It: PureWick female external catheter: a non-invasive urine management system for incontinent women

    Alex Uhr1, Lydia Glick1, Suzanne Barron1, Jillian Zavodnick2, James R. Mark1, Patrick Shenot1, Alana Murphy1
    Canadian Journal of Urology, Vol.28, No.3, pp. 10669-10672, 2021
    Abstract Catheter associated urinary tract infections (CAUTIs) are common hospital-acquired infections and remain a significant medical and financial challenge to the healthcare system. Despite this risk, incontinent women may require prolonged catheterization to accurately monitor urine output and prevent skin breakdown. The PureWick Female External Urinary Catheter is a promising non-invasive urine collection system for use in incontinent women that may help reduce CAUTI rates, maintain skin integrity, accurately quantify urine output, and avoid extra healthcare costs. More >

  • Open AccessOpen Access

    HOW I DO IT

    Using darolutamide in advanced prostate cancer: How I Do It

    Joelle Hamilton
    Canadian Journal of Urology, Vol.28, No.3, pp. 10673-10677, 2021
    Abstract Darolutamide is a nonsteroidal androgen inhibitor FDA approved for the treatment of castration-resistant nonmetastatic prostate cancer (nmCRPC). After decades of offering androgen deprivation therapy (ADT) alone or first-generation androgen receptor blockers for patients whose PSA was rising despite castrate levels of testosterone, there are now three different treatment options to add to ADT. These include apalutamide approved in February 2018, enzalutamide FDA approved in June 2018, and darolutamide approved July 2019. Each of these androgen receptor pathway blockers, when added to ADT or surgical orchiectomy, prolongs metastasis-free-survival (MFS) and median survival (MS). This paper focuses More >

  • Open AccessOpen Access

    ARTICLE

    Perioperative stroke and myocardial infarction in urologic surgery

    Da David Jiang1,2, Kyle A. Gillis1,2, Yiyi Chen3, Jason C. Hedges1, Nicholas H. Chakiryan1,2
    Canadian Journal of Urology, Vol.28, No.3, pp. 10678-10684, 2021
    Abstract Introduction: Perioperative stroke and myocardial infarction are uncommon but devastating thromboembolic complications. There is no comprehensive study detailing these complications for urologic procedures. The primary aim of this study is to determine which urologic procedures and patients carry the highest risk of perioperative stroke and myocardial infarction.
    Materials and methods: The National Surgical Quality Improvement Program data set was reviewed from 2008-2017. Procedures coded under the urology specialty were included, and patients who had a perioperative stroke or myocardial infarction were identified. CPTs were stratified into clinically relevant procedure groups. Two multivariable logistic regression analyses were performed… More >

  • Open AccessOpen Access

    ARTICLE

    Aquablation with subsequent selective bipolar cauterization versus holmium laser enucleation of the prostate (HoLEP) with regard to perioperative bleeding

    Simon Gloger1, Leon Schueller1, Laszlo Paulics1, Thorsten Bach2, Burkhard Ubrig1
    Canadian Journal of Urology, Vol.28, No.3, pp. 10685-10690, 2021
    Abstract Introduction: To compare the surgical methods of Aquablation followed by selective hemostasis by bipolar cauterization with holmium laser enucleation of the prostate (HoLEP) with regard to the risk of perioperative bleeding complications.
    Materials and methods: A retrospective comparison was carried out on a total of 382 patients who had undergone either Aquablation (n = 167) or HoLEP (n = 215) at our hospital between April 2018 and July 2020. The following were studied: Hb loss, the need for packed red blood cell transfusions, and surgical revisions due to bleeding from the prostatic fossa.
    Results: Transfusions were not necessary… More >

  • Open AccessOpen Access

    COMMENTARY

    Aquablation and question of hemostasis

    Abilash Menon, Peter J. Gilling
    Canadian Journal of Urology, Vol.28, No.3, pp. 10691-10691, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    ARTICLE

    Initial transperineal prostate biopsy experience at a high-volume center

    Aaron Berkenwald, Kristian D. Stensland, Luke E. Sebel, Alireza Moinzadeh, William Faust
    Canadian Journal of Urology, Vol.28, No.3, pp. 10692-10698, 2021
    Abstract Introduction: Transperineal prostate biopsy (TPBx) allows for prostate cancer detection with fewer infectious complications when compared to transrectal prostate biopsy (TRUSBx). We evaluated the initial experience of a single physician with no prior TPBx exposure, compared to TRUSBx and MRI/US fusion biopsy (MRIBx) performed by experienced physicians.
    Materials and methods: All consecutive patients undergoing prostate biopsy (June 2019-March 2020) were included. Patient discomfort, procedural time, clinically significant cancer detection rates (csCDR), and 30-day complications were compared between TPBx, TRUSBx, and MRIBx.
    Results: A total of 303 patients underwent biopsy. Comparing TPBx to TRUSBx to MRIBx, median pain scores… More >

  • Open AccessOpen Access

    ARTICLE

    Overactive bladder phenotypes: development and preliminary data

    Jerry G. Blaivas1, Eric S.W. Li2, Linda Dayan3, Max E. Edeson4, Joel Mathew5, Amy L. O’Boyle6, Beede L. Amare7, David C. Chaikin8, Jeffrey P. Weiss9, Karl J. Kreder10
    Canadian Journal of Urology, Vol.28, No.3, pp. 10699-10704, 2021
    Abstract Introduction: The purpose of this study is to develop overactive bladder (OAB) phenotypes that can be used to develop diagnostic and treatment pathways and offer clues to the underlying etiologies of patients with OAB.
    Materials and methods: This is a retrospective, multicenter study of patients with lower urinary tract symptoms (LUTS). Evaluation included a 24-hour bladder diary (24HBD), the lower urinary tract symptoms score (LUTSS) questionnaire, uroflowmetry (Q), and post-void residual urine (PVR) measurement. Patients completed the 24HBD and LUTSS on a smartphone application or paper. Those with an OAB symptom sub-score (OABSS) ≥ 8 were included.… More >

  • Open AccessOpen Access

    COMMENTARY

    Rethinking the approach to evaluation and management of overactive bladder

    Patrick J. Shenot
    Canadian Journal of Urology, Vol.28, No.3, pp. 10705-10705, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    ARTICLE

    Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy

    Kojiro Ohba, Yasuyoshi Miyata, Yuta Mukae, Kensuke Mitsunari, Tomohiro Matsuo, Hideki Sakai
    Canadian Journal of Urology, Vol.28, No.3, pp. 10706-10712, 2021
    Abstract Introduction: To clarify the efficacy and safety of propiverine hydrochloride for incontinence after robot-assisted laparoscopic prostatectomy (RALP)/laparoscopic radical prostatectomy (LRP), along with changes in the urethral pressure profile (UPP) and quality of life in patients treated with propiverine hydrochloride.
    Materials and methods: In this randomized, comparative study, 104 patients who were aware of urinary incontinence after RALP or LRP were assigned to receive propiverine hydrochloride (treatment group) or not (controls). Pad test results, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) scores, and UPP results [including maximum urethral closure pressure (MUCP) and functional urethral length (FUL)], were recorded… More >

  • Open AccessOpen Access

    ARTICLE

    Demographic disparities of penile cancer in Appalachian Kentucky

    Patrick J. Hensley, John Loomis, Jason R. Bylund, Andrew C. James
    Canadian Journal of Urology, Vol.28, No.3, pp. 10713-10718, 2021
    Abstract Introduction: Appalachian Kentucky is a region characterized by poor healthcare literacy and access. We investigate the disparities in demographic distribution and outcomes of penile squamous cell carcinoma (pSCC) in rural Kentucky.
    Materials and methods: Data were retrieved for patients with pSCC from 1995-2015 from the Kentucky Cancer Registry and the Surveillance, Epidemiology and End Results Program (SEER) and were used to investigate differences between Appalachian Kentucky and the remainder of the state and country.
    Results: The incidence of pSCC from 1995-2015 in Appalachian Kentucky was over 60% higher than in non-Appalachian regions (2.6 vs. 1.6 cases/100,000 people). Nearly… More >

  • Open AccessOpen Access

    ARTICLE

    Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma

    Luca Campedel1,†, Thomas Seisen1,†, Justine Varinot2, Géraldine Cancel-Tassin2,3,#, Alain Ruffion4, Emilien Seizilles De Mazancourt4, Myriam Decaussin-Petrucci5, Grégoire Robert6, Nam-Son Vuong6, Magali Philipp7, Eva Compérat2,3,#, Morgan Rouprêt1,3,#, Olivier Cussenot2,3,#
    Canadian Journal of Urology, Vol.28, No.3, pp. 10719-10724, 2021
    Abstract Introduction: Controversy regarding the prognostic and/or predictive role of PD-1 and PD-L1 expression for upper tract urothelial carcinoma (UTUC) could partly be explained by inconsistencies in the immunohistochemistry (IHC) methodology. The objective is to standardize the methodology for routine evaluation of PD-1 and PD-L1 expression in UTUC patients.
    Materials and methods: Twenty-two cases treated with radical nephroureterectomy between 1996 and 2015 at 11 French hospitals were randomly selected to compare different methodologies for evaluation of PD-1 and PD-L1 expression. IHC was carried out on whole tissue sections and 0.6 mm- or 2 mm-core tissue micro-arrays (TMAs) using… More >

  • Open AccessOpen Access

    ARTICLE

    Exceeding the maximum recommended dose of onabotulinumtoxinA in urologic patients

    Bristol B. Whiles1, Joshua Caldwell2, Priya Padmanabhan3
    Canadian Journal of Urology, Vol.28, No.3, pp. 10725-10728, 2021
    Abstract Introduction: Although onabotulinumtoxinA (BTX) is commonly utilized by multiple specialists, it is unclear how often or for what reasons patients receive more than the recommended maximum dose. The goal of this study was to determine if excess BTX use occurs in urologic practice.
    Materials and methods: This retrospective cohort identified patients who underwent intravesical BTX between 01/2013 and 12/2017 at an academic hospital. All BTX administrations for any indication were identified. Excess BTX was defined as receiving greater than the current recommended maximum dosage of 400 units within 3 months.
    Results: A total of 361 patients received intravesical… More >

  • Open AccessOpen Access

    ARTICLE

    The recurrent urinary tract infection health and functional impact questionnaire (RUHFI-Q): design and feasibility assessment of a new evaluation scale

    Stefanie M. Croghan, Jody S.A. Khan, Prem Thomas Jacob, Hugh D. Flood, Subhasis K. Giri
    Canadian Journal of Urology, Vol.28, No.3, pp. 10729-10732, 2021
    Abstract Introduction: We aim to design a tool to assess the impact of recurrent urinary tract infection (rUTI) on quality of life (QoL) in adult women, given the notable absence of an established instrument for this purpose.
    Materials and methods: Best practice guidelines in health-related survey design were reviewed. A literature review informed the creation of an interview guide. Following ethical approval, 10 female patients (23–38 years) with rUTI were invited to participate in phase 1 of questionnaire design; all agreed. Individual semi-structured interviews were conducted exploring the impact of rUTI on patients’ QoL. Interviews were repeated with… More >

Per Page:

Share Link